ImmunityBio announced that the European Commission granted a conditional marketing authorization for its IL‑15 superagonist ANKTIVA on February 18 2026, allowing the drug to be marketed across the European Economic Area. The approval extends ANKTIVA’s reach to 33 countries, including all 27 EU member states plus Iceland, Norway and Liechtenstein, and marks the first time an immunotherapy has been authorized in Europe for BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ.
ANKTIVA is an IL‑15 superagonist that stimulates natural killer and T‑cell activity. It is approved in combination with BCG for patients whose disease has not responded to BCG therapy. The European Commission’s decision was based on the QUILT‑3.032 trial, which reported a 71 % complete‑response rate and a median duration of complete response of 26.6 months, outperforming existing options for this indication.
Financially, ImmunityBio has shown rapid revenue growth driven by ANKTIVA’s commercial traction. Preliminary net product revenue for fiscal 2025 was approximately $113 million, a 700 % year‑over‑year increase, and Q2 2025 revenue reached $26.4 million, up 60 % from Q1 2025. These figures illustrate the company’s accelerating sales momentum and the strong demand for its first‑in‑class therapy.
The announcement was met with a positive market reaction, reflecting investor enthusiasm for the company’s expanded geographic footprint and the first EU approval for this indication. Analysts noted that the conditional nature of the authorization will require ongoing data submission and annual renewal, as well as pricing and reimbursement negotiations across European markets.
Dr. Patrick Soon‑Shiong, Founder and Executive Chairman, said, "The European Commission's authorization of ANKTIVA in combination with BCG marks a defining moment for patients with BCG‑unresponsive NMIBC CIS across Europe, who until now have had no authorized treatment and faced radical cystectomy as their only alternative." The comment underscores the unmet medical need addressed by ANKTIVA and the potential for the drug to become a standard of care.
The conditional approval expands ImmunityBio’s commercial footprint, diversifying its revenue base beyond the United States and Canada. While the new authorization opens a significant revenue stream, the company must continue to provide long‑term safety and efficacy data to the EMA and secure pricing and reimbursement agreements in each market. These requirements represent both a tailwind—through expanded access—and a headwind—through regulatory and commercial hurdles that could impact the speed and scale of commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.